Liquid Biopsy Market Development And Business Intelligence
Summary
- Major factors influencing the growth of the market.
- Leading players & Top Segments.
- Geographic Overview.
Market growth influenced due to following factors-
- Government and global health organizations.
- Increasing preference for non-invasive procedures.
- Technological advancement to augment market revenues.
Global market size-
According to the new market research Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022, at a CAGR of 23.4%.
Leading Players-
The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (OTCPK:ITALY), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
Top Market Segments-
On the basis of product, the liquid biopsy market is broadly segmented into assays kits, instruments, and services. In 2017, the assay kits segment is expected to account for the largest share of this market.
Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications (which includes reproductive health and organ transplant diagnostics). In 2017, cancer applications segment is expected to account for the largest share of the liquid biopsy devices market. Increasing prevalence of cancer and the growing number of research studies on liquid biopsy for cancer applications is driving the growth of this market.
For Details, Download PDF Brochure Here
Geographic Overview -
North America is expected to account for the largest share of the liquid biopsy market in 2017, followed by Europe. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of cancer in the US and Canada, technological advancements in liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.